Published November 2014 | Version v1
Journal article

Clinical effects of EMRT combined with EGFR monoclonal antibody, concurrent chemoradiotherapy, and IMRT alone in nasopharyngeal carcinoma patients: a retrospective case-control study

  • 1. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing (China)

Description

Objective: To compare the treatment outcomes and toxicities in nasopharyngeal carcinoma patients who receive intensity-modulated radiotherapy (IMRT) combined with epidermal growth factor receptor (EGFR) monoclonal antibody, IMRT with concurrent chemotherapy, and IMRT alone. Methods: Sixty-eight previously untreated patients with stage II-IVb nasopharyngeal carcinoma (NPC) who received IMRT combined with cetuximab or nimotuzumab from January 2008 to September 2012 were included in BRT group; the BRT group was matched with 136 patients treated with concurrent chemoradiotherapy (CCRT) and 136 patients treated with IMRT alone at a ratio of 1 : 2 using SAS software. The Kaplan-Meier method was used for calculating survival rates, and the log-rank test was used for survival difference analysis. Prognostic factors were analyzed by the Cox model. Results: The sample sizes of the BRT group, IMRT group, and CCRT group were 14, 69, 47, respectively. The 3-year overall survival (OS), disease-free survival (DFS), locoregional control (LRC), and distant metastasis-free survival (DMFS) of all patients were 91.2%, 80.2%, 93.1%, and 87.2%, respectively. The 3-year OS rates of BRT group, IMRT group, and CCRT group were 91.9%, 92.1%, and 89.9%, respectively (P = 0.379); the 3-year DFS rates of BRT group, IMRT group, and CCRT group were 82.1%, 77.9%, and 81.6%, respectively (P = 0.594); the 3-year LRC rates of BRT group, IMRT group, and CCRT group were 98.2%, 90.6%, and 93.0%, respectively (P = 0.249); the 3-year DMFS rates of BRT group, IMRT group, and CCRT group were 85.2%, 85.2%, and 90.3%, respectively (P = 0.383). Multivariate prognostic analysis showed that T stage and concurrent use of EGFR monoclonal antibody were influential factors for LRC (P = 0.034 and 0.032). Conclusions: IMRT alone yields a good treatment outcome in NPC patients. Although there were no significant differences in OS between the three groups, the BRT group showed an increasing trend in LRC. (authors)

Additional details

Publishing Information

Journal Title
Chinese Journal of Radiation Oncology
Journal Volume
23
Journal Issue
6
Journal Page Range
p. 495-499
ISSN
1004-4221

Optional Information

Notes
1 fig., 4 tabs., 12 refs.; http://dx.doi.org/10.3760/cma.j.issn.1004-4221.2014.06.010